|

Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

RECRUITINGN/ASponsored by University Hospital, Bordeaux
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Bordeaux
Started2025-12-09
Est. completion2028-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07119970

Summary

Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
* JAK2V617F mutation with an allelic burden greater than 1%
* High risk of thrombosis (age over 60 years or prior thrombotic event)
* Diagnosis of MPN within the last 12 months
* Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
* Affiliation with social security
* Signed informed consent

Exclusion Criteria:

* Severe hepatic or renal insufficiency (Creatinine clearance \<30ml/min)
* Patients under legal protection (guardianship or curatorship)
* Patients under heparin treatment at inclusion

Conditions3

CancerMyeloproliferative DisordersMyeloproliferative Neoplasm

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.